Seres Therapeutics (MCRB) Posts Q2 Loss of $1.45/Share

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($1.45), $1.15 worse than the analyst estimate of ($0.30).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds
• MotorK names Roy Toren to board as Helen Protopapas resigns